Your email has been successfully added to our mailing list.

×
0.0160427807486631 0.0160427807486631 0.0133689839572193 -0.117647058823529 -0.165775401069519 -0.13903743315508 -0.227272727272727 -0.24331550802139
Stock impact report

Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine

ALDER BIOPHARMACEUTICALS INC (ALDR) 
Last alder biopharmaceuticals inc earnings: 8/6 04:07 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.alderbio.com/node/5806
Company Research Source: GlobeNewswire
-- Pivotal PROMISE 1 top-line results show eptinezumab met primary and key secondary endpoints -- -- Beginning day 1 after first dose significant reduction in proportion of patients experiencing migraine -- -- Average of 1 in 5 patients had no migraines in any given month over months 1 through 6 -- -- Conference call to be held today, June 27, at 8:00 a.m., ET -- BOTHELL, Wash., June 27, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc., (NASDAQ:ALDR) today announced that eptinezumab, its lead product candidate for migraine prevention, met the primary and key secondary endpoints in PROMISE 1, a Phase 3 pivotal clinical trial evaluating patients with frequent episodic migraine.   PROMISE 1 Highlights PROMISE 1 met the primary endpoint: highly statistically significant reductions in monthly migraine days;Significant Day 1 clinical benefit: =50% reduction in the proportion of patients experiencing a migraine on Day 1 post-dose;Significant 75% responses at all key time point Show less Read more
Impact Snapshot
Event Time:
ALDR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ALDR alerts
Opt-in for
ALDR alerts

from News Quantified
Opt-in for
ALDR alerts

from News Quantified